Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Nat Commun ; 15(1): 2588, 2024 Mar 22.
Article in English | MEDLINE | ID: mdl-38519457

ABSTRACT

We recently achieved the first-in-human transfusion of induced pluripotent stem cell-derived platelets (iPSC-PLTs) as an alternative to standard transfusions, which are dependent on donors and therefore variable in supply. However, heterogeneity characterized by thrombopoiesis-biased or immune-biased megakaryocytes (MKs) continues to pose a bottleneck against the standardization of iPSC-PLT manufacturing. To address this problem, here we employ microRNA (miRNA) switch biotechnology to distinguish subpopulations of imMKCLs, the MK cell lines producing iPSC-PLTs. Upon miRNA switch-based screening, we find imMKCLs with lower let-7 activity exhibit an immune-skewed transcriptional signature. Notably, the low activity of let-7a-5p results in the upregulation of RAS like proto-oncogene B (RALB) expression, which is crucial for the lineage determination of immune-biased imMKCL subpopulations and leads to the activation of interferon-dependent signaling. The dysregulation of immune properties/subpopulations, along with the secretion of inflammatory cytokines, contributes to a decline in the quality of the whole imMKCL population.


Subject(s)
Induced Pluripotent Stem Cells , MicroRNAs , Humans , Megakaryocytes , Induced Pluripotent Stem Cells/metabolism , Blood Platelets/metabolism , Thrombopoiesis/genetics , MicroRNAs/genetics , MicroRNAs/metabolism
2.
Stem Cell Reports ; 16(12): 2861-2870, 2021 12 14.
Article in English | MEDLINE | ID: mdl-34861163

ABSTRACT

Platelet transfusions are critical for severe thrombocytopenia but depend on blood donors. The shortage of donors and the potential of universal HLA-null platelet products have stimulated research on the ex vivo differentiation of human pluripotent stem cells (hPSCs) to platelets. We recently established expandable immortalized megakaryocyte cell lines (imMKCLs) from hPSCs by transducing MYC, BMI1, and BCL-XL (MBX). imMKCLs can act as cryopreservable master cells to supply platelet concentrates. However, the proliferation rates of the imMKCLs vary with the starting hPSC clone. In this study, we reveal from the gene expression profiles of several MKCL clones that the proliferation arrest is correlated with the expression levels of specific cyclin-dependent kinase inhibitors. Silencing CDKN1A and p53 with the overexpression of MBX was effective at stably inducing imMKCLs that generate functional platelets irrespective of the hPSC clone. Collectively, this improvement in generating imMKCLs should contribute to platelet industrialization and platelet biology.


Subject(s)
Cyclin-Dependent Kinase Inhibitor p21/metabolism , Gene Silencing , Induced Pluripotent Stem Cells/metabolism , Megakaryocyte Progenitor Cells/metabolism , Tumor Suppressor Protein p53/metabolism , Blood Platelets/metabolism , Cell Line , Cell Proliferation , Clone Cells , Gene Knockdown Techniques , HEK293 Cells , Humans , Polycomb Repressive Complex 1/metabolism , Proto-Oncogene Proteins c-myc/metabolism , Up-Regulation , bcl-X Protein/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL
...